Insulin action and hypertension: effects of hyperaldosteronism and its treatment

Not Applicable

Completed

• Conditions: Hypertension and insulin resistance; Circulatory System; Hypertension

• Registration Number: ISRCTN21269614
• Lead Sponsor: Belfast Health and Social Care Trust (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2008-09-23
• Last Update Posted: 17 October 2016

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

1. Patients aged under 70 years, either sex
2. Mild essential hypertension

Exclusion Criteria

1. Presence of diabetes mellitus
2. Significant obesity (body mass index [BMI] exceeding 35 kg/m^2)
3. Cardiac, renal or hepatic disease
4. A history of gout
5. Any treatment that may affect insulin action
6. Hyperkalaemia
7. Taking potassium sparing diuretics, potassium supplements or strong inhibitors of CYP 34A
8. Women who are pregnant or breastfeeding
9. Secondary hypertension
10. Diastolic blood pressure outside 80 - 105 mmHg range after placebo run-in of six weeks
11. Not capable of giving informed consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Insulin action will be measured by performing a hyperinsulinaemic, euglycaemic clamp, measured at the end of weeks 6, 18 and 36.

Secondary Outcome Measures

Name	Time	Method
Blood pressure will be measured using a standard automated blood pressure machine, measured at the end of weeks 2, 4, 6, 8, 12, 16, 18, 20, 22, 24, 26, 30, 34 and 36.